Page 3 - Dexamethasone Insert News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dexamethasone insert. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dexamethasone Insert Today - Breaking & Trending Today

Advances in the Treatment of High-Risk MM

Clinical insights on the definition of high-risk multiple myeloma and the treatment of patients with high risk disease, including how the results from the IsKia trial might impact practice. ....

Multiple Myeloma , Newly Diagnosed Multiple Myeloma , Mm Treatment , Transplant Eligible , High Risk , Standard Risk , Gmmg Concept , Mash 2023 ,

Highlights from ASH 2023 in Transplant-Eligible NDMM

Experts in multiple myeloma discuss highlights from the ASH 2023 meeting around transplant-eligible NDMM with particular focus on the PERSEUS and GRIFFIN trials and the clinical implications of the results of these studies. ....

Multiple Myeloma , Newly Diagnosed Multiple Myeloma , Mm Treatment , Transplant Eligible , Griffin Trial , Perseus Trial , Maintenance Therapy , Mash 2023 ,

Delhi: CBI probe ordered by MHA over allegations of fraud at mohalla clinics

The CBI probe was ordered following a recommendation by Delhi Lt Governor V K Saxena on the matter in December last year ....

Saurabh Bharadwaj , Union Home Ministry , Central Bureau Of Investigation , Home Ministry , Central Procurement Agency , Delhi Health , Central Bureau , Standard Quality , Delhi Health Minister Saurabh Bharadwaj , Central Bureau Of Investigation , Cbi Inquiry , Substandard Medicines , Delhi Government Hospitals , Mohalla Clinics , Delhi Lt Governor , K Saxena , Uality Standard Tests , Directorate Of Vigilance , Central Procurement Agency , Supply Chain , Ot Of Standard Quality Drugs , Ife Saving Antibiotics , Preliminary Enquiry , Igilance Department Report , Ailed Drug Tests , Delhi Health Minister ,

New non-steroidal anti-inflammatory can inhibit the cytokine storm and preserve innate immunity

Very early in the COVID-19 pandemic clinical trials in patients hospitalized with COVID-19 confirmed that corticosteroids like dexamethasone reduced mortality, but they were harmful when applied at the first COVID-19 symptoms, due to the weakening of innate antiviral immunity, leading to delayed viral clearance and adverse outcomes in severe viral pneumonias. ....

United States , Sri Lanka , Jose Mar , Generalitat Valenciana , Excellence Program , Spanish Agency Of Medicaments , University Professors , Spanish National Research Council , Global Health Interdisciplinary Platform , Health Products , Severo Ochoa Center , National Phase , Universitat Polit , Pablo Botella , Spanish Agency , South East , Resilience Facility , Global Health Platform , Jesus San Miguel , Universidad De Navarra , Anti Inflammatory , Covid 19 , Fatty Liver , Global Health , Immune Response , Liver Disease ,

Results of the Phase III Randomized IsKia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone as Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients

Francesca Gay, MD, PhD, presents results from the phase III randomized IsKia trial investigating isatuximab-carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in patients with newly diagnosed multiple myeloma. ....

United States , San Diego , Iskia Trial , Pre Transplant Induction , Post Transplant Consolidation , Newly Diagnosed Multiple Myeloma , Multiple Myeloma , Iskia Study , Newly Diagnosed Mm ,